En Es
Categories

Industry News

DiaSorin Completes Acquisition of Luminex to Become a Full-Fledged Diagnostic and Life Science Player

By Labmedica International staff writers
16 Jul 2021

Image: ARIES Systems (Photo courtesy of Luminex Corporation)DiaSorin S.p.A. (?Saluggia?, Italy) has completed the acquisition of Luminex Corporation (Austin, TX, USA), allowing it to gain access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the US.

Additionally, this deal will provide access to Luminex’s applications throughout the Life Science industry, supporting access to academic and scientific research, expanding engagement with biopharma companies, and increasing access to clinical multiplexing assays for future Value Based Care projects.

“The acquisition of Luminex represents an important step in the expansion strategy of DiaSorin. Today, we begin a new phase of our growth, that will position DiaSorin as a fully-fledged diagnostic and life science player, that can offer increasingly sophisticated solutions to customers worldwide, also via the integration of the multiplexing technology that Luminex has pioneered globally,” said Carlo Rosa, CEO of DiaSorin. “The future success of the diagnostics and life science sectors will be increasingly determined by the ability to innovate through cutting-edge technologies and solutions. This is the reason why we believe that Luminex is the perfect asset to boost our growth and to turn us into an even more competitive global company. Now, we have to start the process of cultural integration, in which the people of DiaSorin and Luminex will come together with their passion, resourcefulness and professionalism.”

Related Links:
DiaSorin S.p.A.
Luminex Corporation




E-mail Print
FaceBook Twitter Google+ Linked in

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics, pharmaceutical drug discovery, biomedical research, including genomic and proteomic research, personalized medicine, biodefense research, and food safety. The company’s open-architecture xMAP technology enables large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately.
More info

More articles about Luminex Corporation

13 Apr 2021
DiaSorin to Acquire Luminex to Broaden Positioning in Molecular Diagnostics Space
DiaSorin S.p.A. (?Saluggia?, Italy) has announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation (Austin, TX, USA) for approximately USD 1.8 billion.
Read More

Additional news

21 Jan 2022
Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases
The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application of immunofluorescence assays in clinical diagnostics and research, and growing investments and expenditure in healthcare sector.
Read More
21 Jan 2022
Global Digital X-Ray Systems Market to Be Driven by AI-Based Systems and Robotic Devices
The global digital X-ray systems market was valued at USD 11.74 billion in 2020 and is expected to grow at a CAGR of 7.45% during the forecast period 2021 to 2026, due to the rising number of cancer patients and increasing cases of orthopedic diseases/tumors, cardiovascular diseases (CVD), pneumonia, and dental disorders, among others.
Read More
20 Jan 2022
Illumina and Boehringer Ingelheim Partner to Develop Companion Diagnostics (CDx) for Cancer Treatment
Illumina Inc. (San Diego, CA, USA) has entered into a partnership with Boehringer Ingelheim (Ingelheim am Rhein, Germany; www.boehringer-ingelheim.com) to develop companion diagnostics (CDx) for several programs in the latter’s oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.
Read More
20 Jan 2022
Thermo Fisher and Oncocyte to Jointly Develop IVD Test Kits and Companion Diagnostic Tests in Precision Oncology
Oncocyte Corporation (Irvine, CA, USA) has entered into a development and co-marketing agreement for two distributed in vitro diagnostic (IVD) assays on Thermo Fisher Scientific’s (Waltham, MA, USA) Ion Torrent Genexus System. The agreement also grants Oncocyte rights to develop future companion diagnostics on the Genexus System.
Read More
18 Jan 2022
Global Coagulation Analyzers Market Driven by Growing Awareness About Timely Diagnosis of Blood Clots
The global coagulation analyzers market is expected to reach USD 11.7 billion by 2028, driven by the increasing understanding of blood clots and the fact that they can be avoided with early detection.
Read More
17 Jan 2022
Mobile C-Arms Market to Surpass USD 1.6 Billion in 2027 Due to Growing Preference for Minimally Invasive Surgeries
The global mobile C-arms market is expected to grow at a CAGR of 5.2% from USD 1.07 billion in 2019 to USD 1.61 billion in 2027, driven primarily by an increase in the global geriatric population, rising burden of chronic and acute diseases across the world, increasing volumes of orthopedic, cardiac, neurological, and oncological surgical procedures, and growing preference for minimally invasive surgeries.
Read More
14 Jan 2022
Medlab Middle East to Reveal Latest Innovations and Technologies in Mobile Labs for COVID-19 Testing
The latest technology and innovation in the global fight against COVID-19 and beyond will be on show at the next edition of Medlab Middle East when it returns to the Dubai World Trade Center from 24-27 January 2022 with mobile molecular testing and diagnosis stations, or ‘laboratories on wheels’, from companies such as Seegene, Inc. (Seoul, Korea) taking center stage.
Read More
13 Jan 2022
Global Coagulometers Market to Be Driven by Rising Prevalence of Blood Disorders
The global coagulometers market is being driven by a rise in the incidence and prevalence of blood disorders such as hemophilia that is fueling the demand for more diagnostic tools.
Read More
11 Jan 2022
Medlab Middle East to Return as Standalone Event in 2023
Informa Markets (London, UK), organizers of Medlab Middle East, have announced that the MENA region’s leading exhibition for the laboratory industry will return to a standalone event in 2023.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions